Pharma Two B's P2B001 Drug Shows Promising Results for Early-Stage Parkinson's Disease, Hepion Pharmaceuticals Inc. (HEPA) Stock Poised for Significant Upside Potential.

Pharma Two B's P2B001 shows promising results for early-stage Parkinson's patients, with a low-dose formulation combining pramipexole and rasagiline. Hepion Pharmaceuticals Inc. has a significant upside potential with an average one-year price target of $30.00, representing a 7,217.07% increase from the current share price of $0.41. Analysts have a consensus rating of "Outperform" for the company, suggesting confidence in its potential to deliver substantial returns.